https://www.123articleonline.com/rss/author/425167/mdnews-lineArticles written by MDNews line from 123ArticleOnline.comen-usCopyright (c) 123ArticleOnline.com All rights reserved. https://www.123articleonline.com/articles/1457496/major-breakthrough-five-year-survival-in-nsclc-patients-treated-with-first-line-pembrolizumab Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now!